SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Nectar Lifesciences - Quaterly Results

14 Aug 2023 Evaluate
A slight decline in the revenue of Rs. 3941.22 millions was seen for the June 2023 quarter as against Rs. 4030.23 millions during year-ago period.The Net Profit of the company slipped to Rs. 18.21 millions from Rs. 39.36 millions, a decline of -53.73% on QoQ basis.Operating Profit reported a sharp decline to 360.13 millions from 422.09 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 3941.22 4030.23 -2.21 3941.22 4030.23 -2.21 15246.09 16682.56 -8.61
Other Income 4.73 3.64 29.95 4.73 3.64 29.95 422.39 112.93 274.03
PBIDT 360.13 422.09 -14.68 360.13 422.09 -14.68 979.02 1701.31 -42.45
Interest 176.22 213.66 -17.52 176.22 213.66 -17.52 794.77 788.10 0.85
PBDT 183.91 208.43 -11.76 183.91 208.43 -11.76 184.25 913.21 -79.82
Depreciation 153.32 146.95 4.33 153.32 146.95 4.33 591.19 569.68 3.78
PBT 30.59 61.48 -50.24 30.59 61.48 -50.24 -406.94 343.53 -218.46
TAX 12.38 22.12 -44.03 12.38 22.12 -44.03 -182.37 90.34 -301.87
Deferred Tax 12.38 22.12 -44.03 12.38 22.12 -44.03 -182.37 90.34 -301.87
PAT 18.21 39.36 -53.73 18.21 39.36 -53.73 -224.57 253.19 -188.70
Equity 224.26 224.26 0.00 224.26 224.26 0.00 224.26 224.26 0.00
PBIDTM(%) 7.99 9.06 -11.87 9.14 10.47 -12.75 5.60 8.84 -36.61

Nectar Lifesciences Share Price

12.66 0.25 (2.01%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×